The pharmacokinetics of non-renally cleared drugs in patients with chronic kidney disease is
often unpredictable. Some of this variability may be due to alterations in the expression and …

Background: Chronic renal failure (CRF) has been shown to significantly reduce the
nonrenal clearance and alter bioavailability of drugs predominantly metabolized by the liver …

Renal failure not only alters the renal elimination, but also the non-renal disposition of drugs
that are extensively metabolized by the liver. Although reduced metabolic enzyme activity in …

Unfortunately, there is no endogenous marker for hepatic clearance that can be used as a
guide for drug dosing. In order to predict the kinetic behaviour of drugs in cirrhotic patients …

Chronic renal failure (CRF) is associated with a decrease in drug metabolism. The
mechanism remains poorly understood. The present study investigated the repercussions of …

Numerous drugs with different mechanisms of action and different pharmacologic profiles
are being used with the aim of improving glycemic control in patients with type 2 diabetes …

Background. Patients with chronic renal failure commonly suffer from a secondary form of
complex dyslipidaemia, and may benefit from lipid‐lowering treatment. Atorvastatin has …

Aims To evaluate the effect of renal impairment on the pharmacokinetics and safety of
pioglitazone and its metabolites M‐III and M‐IV with impaired renal function and normal …

The US Food and Drug Administration (FDA) is currently developing a guidance for industry
to replace a previous guidance,“Pharmacokinetics in Patients With Impaired Renal Function …

Hepatic clearance of erythromycin (Ery) is significantly reduced in patients with end stage
renal disease. Since Ery is primarily eliminated via excretion of unchanged drug in the bile …